Children with HIV are not small adults: What is different in pharmacology?

Current Opinion in HIV and AIDS

Volumn 2, Issue 5, 2007, Pages 405-409

  L'homme, Rafaëlla ^a   Warris, Adilia ^a   Gibb, Diana ^b   Burger, David ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Children; HIV; Pharmacokinetics

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EFAVIRENZ; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG EXPOSURE; DRUG INHIBITION; DRUG METABOLISM; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; REVIEW;

EID: 34547913838     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282ced13f     Document Type: Review

References (18)

1. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45:1077-1097. This is an excellent and comprehensive review on the influence of developmental changes in absorption, distribution, metabolism and excretion on drug pharmacokinetics during childhood. General pediatric dose recommendations are proposed.
2. Fraaij PL, Rakhmanina N, Burger DM, de Groot R. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004; 26:122-126.
3. Hirt D, Urien S, Jullien V, et al. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother 2006; 50:910-916. This population pharmacokinetic analysis shows a decrease in the bioavailability of nelfinavir in infants. The authors conclude that children below the age of 2 months may need higher doses than currently recommended.
4. Bergshoeff AS, Fraaij PL, van Rossum AM, et al. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir Ther 2003; 8:215-222.
5. Crommentuyn KM, Scherpbier HJ, Kuijpers TW, et al. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. Pediatr Infect Dis J 2006; 25:538-543.
6. Fulco PP, Vora UB, Bearman GM. Acid suppressive therapy and the effects on protease inhibitors. Ann Pharmacother 2006; 40:1974-1983.
7. Ikeda T, Ch'ng TW, Oleske JM. Recommendations in pediatric antiretroviral therapy. Expert Opin Pharmacother 2007; 8:155-166. This brief review clearly summarizes the text of the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection that were developed for the US and updated in October 2006.
8. Macassa E, Delaugerre C, Teglas JP, et al. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Pediatr Infect Dis J 2006; 25:809-814. The change to a once-daily treatment including ritonavir-boosted atazanavir in 23 extensively pretreated children between 10 and 19 years old was associated with a significant risk of virological failure.
9. Plipat N, Cressey TR, Vanprapar N, Chokephaibulkit K. Efficacy and plasma concentrations of indinavir when boosted with ritonavir in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2007; 26:86-88.
10. Patel IH, Zhang X, Nieforth K, et al. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005; 44:175-186.
11. Bellibas SE, Siddique Z, Dorr A, et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004; 23:1137-1141.
12. Zhang X, Lin T, Bertasso A, et al. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. J Clin Pharmacol 2007; 47:510-517. The results of this population pharmacokinetic analysis confirm the appropriateness of body weight-based pediatric enfuvirtide dosing.
13. King JR, Acosta EP. Tipranavir: a novel nonpeptidic protease inhibitor of HIV. Clin Pharmacokinet 2006; 45:665-682.
14. Oldfield V, Plosker GL. Lopinavir/Ritonavir: a review of its use in the management of HIV infection. Drugs 2006; 66:1275-1299.
15. Jullien V, Urien S, Hirt D, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 2006; 50:3548-3555. The unexpected finding of decreased exposure to lopinavir in neonates makes this paper of outstanding interest.
16. van der Lee M, Verweel G, de Groot R, Burger D. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Antivir Ther 2006; 11:439-445. This study showed higher variability in lopinavir trough levels in children than in adults treated once daily. Subtherapeutic trough levels were more often experienced in younger children.
17. Verweel G, Sharland M, Lyall H, et al. Nevirapine use in HIV-1-infected children. AIDS 2003; 17:1639-1647.
18. Ellis JC, L'homme RFA, Ewings FM, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12:253-260. This important study demonstrated that it is difficult to achieve adequate nevirapine levels with divided adult FDC antiretroviral tablets in children without the risk of overdosing with stavudine. Development of appropriate pediatric FDC tablets is essential for the treatment of HIV-infected children in resource-limited settings.